Acute coronary syndrome (ACS) remains a significant cause of morbidity and mortality worldwide. The management of ACS has seen remarkable advancements over the past years, with best practices being continuously refined to improve patient outcomes. This article aims to provide a comprehensive guide on the latest advancements and best practices in ACS management.
Recent years have witnessed significant advancements in the management of ACS, particularly in the areas of pharmacotherapy and interventional cardiology. Novel antithrombotic agents such as ticagrelor and prasugrel have shown superior efficacy and safety profiles compared to traditional antiplatelet therapies. Additionally, the development of drug-eluting stents has significantly reduced the risk of restenosis in patients undergoing percutaneous coronary intervention (PCI).
Early diagnosis and risk stratification remain the cornerstone of ACS management. The use of high-sensitivity cardiac troponin assays has improved the accuracy of ACS diagnosis. Furthermore, risk stratification tools such as the GRACE score are instrumental in guiding therapeutic decisions. Current guidelines recommend immediate reperfusion therapy for ST-segment elevation myocardial infarction (STEMI) patients, with primary PCI being the preferred method when feasible. For non-ST-segment elevation ACS (NSTE-ACS) patients, an early invasive strategy is recommended for high-risk patients, while a conservative approach may be appropriate for lower-risk patients.
Emerging research is exploring the potential of precision medicine in ACS management. Genomic studies may help identify patients at high risk of adverse events or those likely to benefit from specific therapies. Additionally, the use of artificial intelligence in predicting ACS outcomes and guiding therapy is a promising area of research.
In conclusion, the management of ACS has seen significant advancements, and best practices continue to evolve. Healthcare professionals should stay abreast of these developments to provide optimal care for ACS patients. Future research in precision medicine and artificial intelligence may further revolutionize ACS management.
1.
Researchers use genomic technology to investigate aggressive skin cancer linked to burn scars
2.
The Growing Role of AI in Cancer Treatment
3.
Tafasitamab Regimen Improves PFS in Relapsed/Refractory Follicular Lymphoma
4.
Lower Prostate Cancer Mortality Linked to Unavailable Clinical Trials.
5.
Powerlifting through breast cancer: How a breast cancer survivor defied chemotherapy with strength training
1.
Drug Exposure in Tumor Microenvironments: Mechanisms, Clinical Implications, and Emerging Strategies
2.
Proteoform Networks in Blood Disorders: Mechanisms, Clinical Implications, and Emerging Therapeutic Strategies
3.
Antibody-Drug Conjugates and the Dawn of Targeted Cancer Therapy in 2025
4.
Revolutionizing Oncology Trials: Optimization, Matching, Diversity, and Decentralization
5.
Direct Oral Anticoagulants (DOACs) in Atrial Fibrillation: A Comprehensive Review
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion- Part II
2.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
3.
Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment
4.
How Multidisciplinary Teams Support Modern Cancer Care
5.
Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation